Stability Indicating RP-HPLC method development and validation for simultaneous quantification of antihistaminic &amp; anti-asthmatic drug in bulk and tablet dosage form

Dilip A Patil,Jitendra K Sonawane,Prashant B Patil,Satish L Jadhav,Balasaheb S Jadhav

doi:10.18231/j.jpbs.2020.003

Abstract

Stability Indicating RP-HPLC method development and validation for simultaneous quantification of antihistaminic & anti-asthmatic drug in bulk and tablet dosage form - JPBS- Print ISSN No: - Online ISSN No:- 2320-1924 Article DOI No:- 10.18231/j.jpbs.2020.003, Journal of Pharmaceutical and Biological Sciences-J Pharm B

Highlights

Levocetirizine dihydrochloride (LEV), (2-[4-(R)-(4chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxyacetate dihydrochloride) is a third-generation non-sedative antihistamine, H1 receptor antagonist.[1,2,3,4,5,6] does block histamine receptors
Recent studies have shown that treatment with concomitant administration of anti-leukotriene and antihistamines for allergic rhinitis provides a significantly enhanced symptom relief compared to the mild improvement in rhinitis symptoms with each drug alone.[5,9,10,11]
The best peak form and maximum separation was achieved with the mobile phase composition of Acetonitrile and Phosphate buffer pH-7.0 (60:40), peak symmetry and reproducibility was obtained with Hypersil BDS C18, 250 mm and 4.6 mm, 5 μm column

Summary

Introduction

Levocetirizine dihydrochloride (LEV), (2-[4-(R)-(4chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxyacetate dihydrochloride) (fig. 1) is a third-generation non-sedative antihistamine, H1 receptor antagonist.[1,2,3,4,5,6] does block histamine receptors. 1) is a third-generation non-sedative antihistamine, H1 receptor antagonist.[1,2,3,4,5,6] does block histamine receptors This is used to treat several allergic reactions, i.e., allergic rhinitis, idiopathic urticaria, hay fever, etc.[7] The half-dose form of LCTZ (2.5 mg) has been clinically proven to have equivalent antihistaminic effectiveness in the treatment of allergic rhinitis and chronic idiopathic urticaria to the normal amount of cetirizine (5.0 mg),[2,8]. Montelukast Sodium (MON) (1-[[[(1R)-1-[3-(1E)-2(7-chloro-2-quinolinyl) ethenyl] phenyl]-3-[2-(1hydroxy-1-methylethyl) phenyl] -propyl] thio] methyl cyclopropaneacetic acid, monosodium salt (Fig. 2) is a white colored powder which is soluble in ethanol, methanol and water and is practically insoluble in acetonitrile. Journal of Pharmaceutical and Biological Sciences, January-June, 2020;8(1):[12,13,14,15,16,17,18,19,20,21,22]

Objectives

Results

Conclusion